Serum-EVs suppressed miR-526b-3p-mediated inhibition of epithelial V-like antigen 1 (EVA1), which has been verified to be implicated in tumour progression and drug response (Wang et al., 2022). This evidence concerns the gene MPZL2 and neoplasm.